BDTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.87%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Black Diamond Therapeutics Insider Trading History Chart

Black Diamond Therapeutics Share Price & Price History

^$2.62

▼ -0.23 (-8.07%)

As of 11/15/2024 01:00 AM ET

Days: 30 | 90 | 365

The Crypto That’s Making Wall Street Sweat

From Crypto 101 Media | Ad

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

Black Diamond Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/17/2023	Growth N V Biotech	Major Shareholder	Buy	400,000	$2.34	$936,000.00	8,517,839
7/5/2023	Ali Behbahani	Director	Buy	1,000,000	$5.00	$5,000,000.00	4,448,757
6/30/2023	Growth N V Biotech	Major Shareholder	Buy	1,000,000	$5.00	$5,000,000.00	8,117,839
6/27/2023	David M Epstein	Insider	Sell	25,000	$6.70	$167,500.00	671,423
6/27/2023	Growth N V Biotech	Major Shareholder	Buy	1,740,000	$5.49	$9,552,600.00	7,117,839
10/27/2022	Growth N V Biotech	Major Shareholder	Buy	191,678	$1.87	$358,437.86	5,105,064
10/21/2022	Growth N V Biotech	Major Shareholder	Buy	87,850	$1.51	$132,653.50	4,913,386
10/19/2022	Growth N V Biotech	Major Shareholder	Buy	77,689	$1.32	$102,549.48	4,771,802
6/29/2022	Fang Ni	Insider	Buy	25,000	$2.44	$61,000.00	69,026
4/27/2022	Growth N V Biotech	Major Shareholder	Buy	150,000	$2.66	$399,000.00	4,438,402
4/18/2022	Growth N V Biotech	Major Shareholder	Buy	150,000	$3.29	$493,500.00	4,138,402
4/12/2022	Growth N V Biotech	Major Shareholder	Buy	150,000	$3.42	$513,000.00	3,885,846

The Crypto That’s Making Wall Street Sweat

From Crypto 101 Media | Ad

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

SEC Filings (Institutional Ownership Changes) for Black Diamond Therapeutics (NASDAQ:BDTX)

95.47% of Black Diamond Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Black Diamond Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	944,877	$4.11M	0.0%	+12.2%	1.670%
11/15/2024	Barclays PLC	78,151	$0.34M	0.0%	+201.9%	0.138%
11/15/2024	Wellington Management Group LLP	204,957	$0.89M	0.0%	+12.8%	0.362%
11/15/2024	State Street Corp	809,196	$3.52M	0.0%	+17.2%	1.430%
11/15/2024	Point72 Asset Management L.P.	697,125	$3.03M	0.0%	N/A	1.232%
11/14/2024	Vestal Point Capital LP	5,028,500	$21.87M	1.7%	+139.5%	8.887%
11/14/2024	Walleye Capital LLC	11,195	$49K	0.0%	N/A	0.020%
11/14/2024	MetLife Investment Management LLC	22,286	$97K	0.0%	+129.1%	0.039%
11/13/2024	FMR LLC	179,068	$0.78M	0.0%	N/A	0.316%
11/12/2024	Charles Schwab Investment Management Inc.	109,224	$0.48M	0.0%	+6.9%	0.193%
11/9/2024	Intech Investment Management LLC	12,907	$56K	0.0%	N/A	0.023%
11/6/2024	Cornercap Investment Counsel Inc.	22,583	$98K	0.0%	-53.1%	0.040%
10/21/2024	Foundations Investment Advisors LLC	102,300	$0.45M	0.0%	-9.9%	0.182%
10/16/2024	Vontobel Holding Ltd.	15,723	$68K	0.0%	N/A	0.028%
8/16/2024	Algert Global LLC	28,501	$0.13M	0.0%	N/A	0.051%
8/15/2024	The Manufacturers Life Insurance Company	60,189	$0.28M	0.0%	N/A	0.107%
8/15/2024	Affinity Asset Advisors LLC	650,000	$3.03M	0.3%	N/A	1.155%
8/14/2024	Squarepoint Ops LLC	25,351	$0.12M	0.0%	-85.2%	0.045%
8/14/2024	Marshall Wace LLP	94,537	$0.44M	0.0%	N/A	0.168%
8/14/2024	Ally Bridge Group NY LLC	835,000	$3.89M	2.3%	N/A	1.484%
8/12/2024	Marathon Trading Investment Management LLC	19,116	$89K	0.0%	-79.8%	0.034%
8/9/2024	Renaissance Technologies LLC	263,900	$1.23M	0.0%	+24.1%	0.469%
8/9/2024	Dimensional Fund Advisors LP	200,044	$0.93M	0.0%	+79.1%	0.356%
8/3/2024	TD Asset Management Inc	266,312	$1.24M	0.0%	+275.9%	0.473%
8/2/2024	Foundations Investment Advisors LLC	113,550	$0.53M	0.0%	+17.7%	0.202%
8/1/2024	Rhumbline Advisers	46,850	$0.22M	0.0%	+10,334.3%	0.083%
7/26/2024	Bank of New York Mellon Corp	108,959	$0.51M	0.0%	N/A	0.194%
7/12/2024	SG Americas Securities LLC	23,146	$0.11M	0.0%	N/A	0.041%
5/17/2024	Artal Group S.A.	1,046,517	$5.31M	0.1%	-48.9%	1.860%
5/16/2024	Kennedy Capital Management LLC	717,183	$3.64M	0.1%	-3.2%	1.275%
5/15/2024	Bellevue Group AG	8,517,839	$43.19M	0.7%	-0.2%	15.142%
5/10/2024	Acadian Asset Management LLC	170,510	$0.86M	0.0%	+13.8%	0.325%
5/10/2024	Vanguard Group Inc.	1,905,300	$9.66M	0.0%	-2.1%	3.627%
5/7/2024	Susquehanna Fundamental Investments LLC	16,218	$82K	0.0%	N/A	0.031%
2/14/2024	Bellevue Group AG	8,535,839	$23.99M	0.4%	+4.9%	16.533%
2/14/2024	Pale Fire Capital SE	51,100	$0.14M	0.0%	N/A	0.099%
2/7/2024	Jump Financial LLC	38,888	$0.11M	0.0%	+245.0%	0.075%
1/30/2024	Cornercap Investment Counsel Inc.	82,784	$0.23M	0.0%	N/A	0.160%
12/6/2023	Citigroup Inc.	61,348	$0.18M	0.0%	N/A	0.119%
11/14/2023	Newtyn Management LLC	205,000	$0.59M	0.1%	+2.5%	0.397%
11/14/2023	Deerfield Management Company L.P. Series C	930,447	$2.67M	0.1%	-48.3%	1.802%
11/13/2023	CHI Advisors LLC	720,000	$2.07M	0.6%	-4.0%	1.395%
11/13/2023	Algert Global LLC	19,820	$57K	0.0%	N/A	0.038%
11/7/2023	Barclays PLC	322,246	$0.93M	0.0%	+159.1%	0.625%
11/7/2023	Jump Financial LLC	11,272	$32K	0.0%	N/A	0.022%
8/22/2023	CHI Advisors LLC	750,000	$3.79M	1.1%	N/A	2.054%
8/15/2023	RA Capital Management L.P.	3,525,754	$17.81M	0.3%	+36.1%	9.657%
8/14/2023	Bellevue Group AG	8,135,839	$41.09M	0.6%	+50.8%	22.282%
8/14/2023	Rock Springs Capital Management LP	563,233	$2.84M	0.1%	N/A	1.543%
8/14/2023	Driehaus Capital Management LLC	696,969	$3.52M	0.0%	N/A	1.909%
8/11/2023	VR Adviser LLC	353,629	$1.79M	0.3%	N/A	0.969%
8/11/2023	Artal Group S.A.	2,046,517	$10.34M	0.3%	+24.3%	5.605%
8/10/2023	Monashee Investment Management LLC	170,000	$0.86M	0.2%	N/A	0.466%
8/8/2023	Candriam S.C.A.	500,009	$2.53M	0.0%	N/A	1.370%
8/4/2023	Maven Securities LTD	187,513	$0.95M	0.0%	N/A	0.514%
8/2/2023	Bank of Montreal Can	15,000	$76K	0.0%	N/A	0.041%
7/12/2023	Herbst Group LLC	13,635	$69K	0.0%	N/A	0.037%
7/12/2023	Beacon Capital Management LLC	15,615	$79K	0.0%	-56.2%	0.043%
7/10/2023	AE Wealth Management LLC	15,920	$80K	0.0%	-55.7%	0.044%
5/15/2023	EcoR1 Capital LLC	1,191,094	$2.25M	0.1%	+322.2%	3.263%
5/8/2023	Federated Hermes Inc.	13,185	$25K	0.0%	-91.5%	0.036%
2/14/2023	EcoR1 Capital LLC	282,131	$0.51M	0.0%	N/A	0.776%
2/10/2023	K2 Principal Fund L.P.	158,192	$0.29M	0.0%	-84.7%	0.435%
1/12/2023	Marquette Asset Management LLC	34,400	$62K	0.0%	N/A	0.095%
11/14/2022	Ergoteles LLC	50,347	$85K	0.0%	-54.2%	0.138%
11/10/2022	Connor Clark & Lunn Investment Management Ltd.	82,881	$0.14M	0.0%	+572.2%	0.228%
10/18/2022	Bailard Inc.	21,281	$36K	0.0%	-63.6%	0.059%
10/5/2022	Beacon Capital Management LLC	35,615	$88K	0.0%	+48.4%	0.098%
9/16/2022	Federated Hermes Inc.	159,548	$0.39M	0.0%	-84.6%	0.439%
8/11/2022	Healthcare of Ontario Pension Plan Trust Fund	73,100	$0.18M	0.0%	-79.5%	0.201%
8/5/2022	Connor Clark & Lunn Investment Management Ltd.	12,330	$30K	0.0%	N/A	0.034%
8/3/2022	AE Wealth Management LLC	36,385	$90K	0.0%	+45.8%	0.100%
7/27/2022	Bailard Inc.	58,500	$0.14M	0.0%	N/A	0.161%
5/6/2022	Los Angeles Capital Management LLC	88,887	$0.25M	0.0%	+63.8%	0.245%
4/18/2022	AE Wealth Management LLC	24,963	$69K	0.0%	+54.7%	0.069%
2/14/2022	PDT Partners LLC	74,036	$0.40M	0.0%	-27.3%	0.204%
2/14/2022	DAFNA Capital Management LLC	206,100	$1.10M	0.3%	N/A	0.569%
2/11/2022	Bioimpact Capital LLC	239,888	$1.28M	0.2%	-3.5%	0.662%
2/3/2022	Cambridge Investment Research Advisors Inc.	11,031	$59K	0.0%	N/A	0.030%
2/2/2022	New York State Common Retirement Fund	10,694	$57K	0.0%	-36.0%	0.030%
1/20/2022	AE Wealth Management LLC	16,135	$86K	0.0%	N/A	0.045%
11/16/2021	Schonfeld Strategic Advisors LLC	14,900	$0.13M	0.0%	-47.7%	0.041%
11/16/2021	Squarepoint Ops LLC	20,092	$0.17M	0.0%	N/A	0.055%
11/16/2021	Two Sigma Advisers LP	181,300	$1.53M	0.0%	+115.3%	0.500%
11/16/2021	Two Sigma Investments LP	296,806	$2.51M	0.0%	-28.3%	0.819%
11/16/2021	Voloridge Investment Management LLC	137,441	$1.16M	0.0%	+8.9%	0.379%
11/16/2021	BioImpact Capital LLC	248,506	$2.10M	0.3%	N/A	0.686%
11/15/2021	Deerfield Management Company L.P. Series C	760,128	$6.43M	0.1%	-27.4%	2.098%
11/15/2021	Dynamic Technology Lab Private Ltd	10,307	$87K	0.0%	N/A	0.028%
11/15/2021	GSA Capital Partners LLP	69,299	$0.59M	0.1%	-4.9%	0.191%
11/15/2021	Martingale Asset Management L P	36,920	$0.31M	0.0%	+22.6%	0.102%
11/12/2021	Credit Suisse AG	50,586	$0.43M	0.0%	N/A	0.140%
11/12/2021	Geode Capital Management LLC	349,980	$2.96M	0.0%	-2.7%	0.966%
11/12/2021	Bank Julius Baer & Co. Ltd Zurich	30,000	$0.25M	0.0%	-50.4%	0.083%
11/10/2021	Goldman Sachs Group Inc.	126,106	$1.07M	0.0%	-34.8%	0.348%
11/10/2021	Citigroup Inc.	48,898	$0.41M	0.0%	-13.0%	0.135%
11/10/2021	Healthcare of Ontario Pension Plan Trust Fund	130,300	$1.10M	0.0%	N/A	0.360%
11/9/2021	BlackRock Inc.	2,190,630	$18.53M	0.0%	+1.7%	6.050%
11/8/2021	Los Angeles Capital Management LLC	54,257	$0.46M	0.0%	-8.6%	0.150%
11/4/2021	Deutsche Bank AG	24,963	$0.21M	0.0%	-78.6%	0.069%

Data available starting January 2016

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $2.62

$2.62

$2.86

50 Day Range

MA: $3.83

$2.62

$6.19

52 Week Range

Now: $2.62

$2.09

$7.66

Volume

442,206 shs

Average Volume

598,251 shs

Market Capitalization

$148.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.51

Who are the company insiders with the largest holdings of Black Diamond Therapeutics?: Black Diamond Therapeutics' top insider shareholders include:
Growth N V Biotech (Major Shareholder)
Ali Behbahani (Director)
David M Epstein (Insider)
Learn More about top insider investors at Black Diamond Therapeutics.
Who are the major institutional investors of Black Diamond Therapeutics?: Black Diamond Therapeutics' top institutional shareholders include:
Vestal Point Capital LP — 8.89%
Ikarian Capital LLC — 0.00%
Geode Capital Management LLC — 1.67%
State Street Corp — 1.43%
Point72 Asset Management L.P. — 1.23%
LMR Partners LLP — 0.00%
Learn More about top institutional investors of Black Diamond Therapeutics stock.
Which major investors are selling Black Diamond Therapeutics stock?: During the last quarter, BDTX stock was sold by these institutional investors:
Cornercap Investment Counsel Inc.
Foundations Investment Advisors LLC
Which major investors are buying Black Diamond Therapeutics stock?: In the previous quarter, BDTX stock was purchased by institutional investors including:
Vestal Point Capital LP
Ikarian Capital LLC
Point72 Asset Management L.P.
LMR Partners LLP
FMR LLC
State Street Corp
Geode Capital Management LLC
Jane Street Group LLC
In the last year, these company insiders have bought Black Diamond Therapeutics stock:
Growth N V Biotech (Major Shareholder)
Ali Behbahani (Director)
Learn More investors buying Black Diamond Therapeutics stock.